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Abstract
Although metabolic syndrome is associated with increased risk of cardiovascular disease
and events, its added prognostic value beyond its components remains unknown. This
study compared the prevalence, severity of coronary artery disease (CAD), and prognosis
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of patients with metabolic syndrome to those with individual metabolic syndrome compo-
nents. The study cohort consisted of 27125 consecutive individuals who underwent64-
detector row coronary CT angiography (CCTA) at 12 centers from 2003 to 2009. Metabolic
syndrome was defined as per NCEP/ATP III criteria. Metabolic syndrome patients (n=690)
were matched 1:1:1 to those with 1 component (n=690) and 2 components (n=690) of meta-
bolic syndrome for age, sex, smoking status, and family history of premature CAD using
propensity scoring. Major adverse cardiac events (MACE) were defined by a composite of
myocardial infarction (MI), acute coronary syndrome, mortality and late target vessel revas-
cularization. Patients with 1 component of metabolic syndrome manifested lower rates of
obstructive 1-, 2-, and 3-vessel/left main disease compared to metabolic syndrome patients
(9.4% vs 13.8%, 2.6% vs 4.5%, and 1.0% vs 2.3%, respectively; p<0.05), while those with
2 components did not (10.5% vs 13.8%, 2.8% vs 4.5% and 1.3% vs 2.3%, respectively;
p>0.05). At 2.5 years, metabolic syndrome patients experienced a higher rate of MACE
compared to patients with 1 component (4.4% vs 1.6%; p=0.002), while no difference ob-
served compared to individuals with 2 components (4.4% vs 3.2% p=0.25) of metabolic syn-
drome. In conclusion, Metabolic syndrome patients have significantly greater prevalence,
severity, and prognosis of CAD compared to patients with 1 but not 2 components of
metabolic syndrome.
Introduction
By the National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP III),
metabolic syndrome (MetS) is defined by the presence of at least 3 components of obesity, dys-
lipidemia, hypertension or treated hypertension, and elevated fasting plasma glucose levels
[1,2]. The presence of MetS is believed to manifest through dysregulation of energy utilization
established through insulin resistance. An array of studies has observed worsened cardiovascu-
lar prognosis and heightened mortality for individuals with MetS [3–7]. However, the various
definitions of MetS, the presence of multiple subtypes of MetS with varying treatment strate-
gies, as well as its pathogenic uncertainty has elicited questions as to whether the presence of
MetS confers incremental risk of major adverse cardiovascular events (MACE) over the sum of
its parts [7–10].
Coronary computed tomography angiography (CCTA) is a noninvasive diagnostic tool that
has high diagnostic performance both for detection and exclusion of CAD [11]. Multicenter
studies have demonstrated a prognostic utility for individuals with CCTA-identified CAD
[12–14]. In this present study of individuals undergoing CCTA, we sought to determine wheth-
er or not MetS is predictive of CAD prevalence, extent and severity, and incident MACE be-
yond that of its individual components.
Materials and Methods
The COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multi-
center (CONFIRM) Registry is a dynamic, prospective, international, multicenter, observation-
al registry of 27125 consecutive patients who underwent 64 detector row CCTA for
suspected CAD at 12 centers from 2003 to 2009. The study rationale and design has been previ-
ously described [15].
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Before CCTA, we prospectively collected information on presence of CAD risk factors.
Hypertension was defined as history of high blood pressure or active treatment with anti-
hypertensive medications. Diabetes was defined by a previous diagnosis of elevated fasting
plasma glucose126 mg/dl and/or use of insulin or hypoglycemic agents. Dyslipidemia was
defined as known but untreated dyslipidemia or treatment with lipid lowering medications,
and included elevated levels of low density lipoproteins, elevated triglycerides, or low levels
high density lipoproteins. Body mass index (BMI) was utilized as a measure of obesity, and was
calculated as weight in kilograms divided by square of height in meters, with value30
considered obese.
CCTA was performed using multiple scanner platforms (Light speed VCT, GE Healthcare,
Milwaukee, WI; Somatom Definition CT, Siemens, Ehrlangen, Germany; Somatom Definition
Flash CT, Siemens, Ehrlangen, Germany). Contrast (80 to 140 ml) was injected, and whole-
volume image acquisition was completed in a single breath-hold. The scan parameters were
64×0.625/0.750 mm collimation and tube voltage 100 or 120 kVp, and the tube current was as-
signed based on body size and scanner platform.
Helical or axial scan data were obtained with retrospective or prospective electrocardiogram
gating, respectively. Acquired image data were initially reconstructed in mid-diastole (always)
and end-systole (when available) and the phase with the least amount of coronary artery mo-
tion was chosen for analysis. Reconstructed data were evaluated by highly experienced readers
(Level III equivalent and/or board certified in CCTA) using all necessary post processing tech-
niques to determine the presence of CAD in any visible segment 2 mm in diameter. A
16-segment American Heart Association coronary artery tree model was used [16]. In each
coronary artery segment, coronary atherosclerosis was defined as tissue structures>1 mm2
that existed either within the coronary artery lumen or adjacent to the coronary artery lumen
that could be discriminated from surrounding pericardial tissue, epicardial fat, or the vessel
lumen itself and identified in2 planes. Coronary lesions were quantified for luminal diameter
stenosis by visual estimation and were graded as none (0% luminal stenosis), non-obstructive
(1–49%) and obstructive (50%). Plaque composition in each coronary segment was reported
as calcified, non-calcified, or partially calcified [17].
Plaque severity was graded at per-vessel and per-patient level. For purposes of classification
for per-vessel analyses, we considered four arterial territories: (1) left main (LM) artery, (2) left
anterior descending (LAD) artery, (3) left circumflex (LCx) artery, and (4) right coronary ar-
tery (RCA). Obstructive CAD in the diagonal branches, obtuse marginal branches, and pos-
terolateral branches was considered to be part of the LAD, LCx, and RCA system, respectively.
The posterior descending artery (PDA) was considered as part of the RCA or LCx system, de-
pending upon coronary artery dominance.
MetS was defined as the presence of 3 or more of the following: (1) diabetes mellitus or use
of hypoglycemics, (2) dyslipidemia, (3) hypertension or use of anti-hypertensive medications,
or (4) elevated BMI30. We used a history of diabetes or use of insulin/oral hypoglycemic
medication as a marker for impaired fasting blood glucose, BMI30 as a marker for waist cir-
cumference, and hypertension or use of anti-hypertensive medications as a marker for elevated
blood pressure [18,19].
MACE were defined by a component endpoint of all-cause mortality, non-fatal myocardial
infarction (MI) or unstable angina (UA), and late target revascularization90 days after
CCTA in accordance with ACC/AHA guidelines and the ESC/ACCF/AHA/WHF Universal
Definition of Myocardial Infarction [20–22]. Follow-up for MACE was performed at each in-
stitution by a dedicated physician and/or research nurse. Sites within the United States (US) as-
certained death by query or by the National Death Index. In non-US sites, ascertainment of
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death was determined by direct interview and/or telephone contact, and/or review of medical
records. Additional event ascertainment including MI, was performed at certain sites by direct
interview, telephone contact, or review of medical records.
Continuous variables are presented as mean ± SD and were evaluated using a Student un-
paired t-test or a Wilcoxon rank-sum test, as appropriate. Categorical variables are presented
as frequencies with percentages and evaluated using the Pearson Chi-square test or Fisher
Exact test where there were cell counts<6. Comparisons were made between those MetS pa-
tients versus patients without MetS. Statistical significance was accepted for two-sided p-values
<0.05. All calculations were performed using STATA version 11 (StataCorp, College Station,
Texas). For outcome statistics, annualized event rates were calculated by dividing the number
of MACE by person years, and with MACE compared using the log-rank test and visualized
using Kaplan-Meier graphs. Cox regression was used to evaluate MetS subgroups, adjusting for
age, gender, and chest pain type. The assumption of proportion hazards was verified using
Schoenfeld residuals.
Propensity scores were derived using logistic regression to match the MetS patients to patients
without MetS, both for those with 1 component of MetS as well as for those with 2 components
of MetS. Propensity scores accounted for age, gender, smoking, and family history; and consisted
of the resulting predicted probabilities of a logistic regression model predicting the presence of
MetS versus those with individual components of MetS. The resulting propensity scores were
then applied 1:1 to match every patient without MetS to a corresponding patient with MetS
using the Mahalanobis nearest-neighbor matching algorithm [23]. This matching resulted in
1:1:1 matching of 690:690:690 patients with 1 or 2 components of MetS and MetS, respectively.
Results
From 27125 consecutive patients undergoing CCTA, 3900 patients with any clinical compo-
nent of MetS were identified, with 690 patients fulfilling the diagnostic criteria for MetS
(Table 1). Propensity score matching resulted in mean caliper differences of 0.0004±0.001 and
0.0005±0.001 for patients with 1 or 2 components of MetS, respectively. Standardized differ-
ences were<0.1. Among matched patients with1 component of MetS and MetS, no differ-
ences were observed for age, sex, family history of CAD, smoking status, dyslipidemia, and
presenting symptom type; although hypertension, diabetes mellitus and obesity were more
common for patients with MetS (p<0.001) (Table 1).
By CCTA, extent and severity of CAD was significantly different for patients with versus
without MetS. For individuals with 1 component of MetS, patients with MetS manifested a
lower rate of normal coronaries, and higher rates of non-obstructive and obstructive CAD; as
well as those with more 1-vessel, 2-vessel, 3-vessel/left main disease and a higher stenosis score
(Table 2). When compared to patients with 2 components of MetS, individuals with MetS dem-
onstrated lower rates of normal coronary arteries and higher rates of obstructive CAD. For pa-
tients with 2 components of MetS, the prevalence of non-obstructive plaque, presence of
obstructive 1-vessel, 2-vessel and 3-vessel/LM disease were not significantly different when
compared to patients with MetS (p>0.05).
At median follow-up of 2.5 years (interquartile range 1.5–3.5 years), 63 MACE events oc-
curred. The presence of MetS was associated with higher rates and risk of mortality and MACE
but similar rates and risk of MI (Table 3, Table 4).
Discussion
This study from the CONFIRM registry is the first prospective, multicenter analysis to provide
data on the per-patient, per-vessel, and per-segment extent, prevalence and severity of CAD by
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CCTA in individuals with versus without MetS who were similar in age, sex, family history of
premature CAD, and smoking history. We observed a higher prevalence, extent and severity of
CAD and MACE rates in patients with versus without MetS, a finding that was associated with
worsened prognosis for MACE and their individual components. When further stratified, how-
ever, the higher prevalence of CAD and worsened prognosis for MetS patients versus those
without MetS was limited to patients with a single clinical component of MetS and was no dif-
ferent for those individuals with 2 clinical components of MetS.
The coexistence of clinical CAD risk factors that include impaired fasting glucose, obesity,
and atherogenic dyslipidemia has been termed MetS, a condition that is defined as an “aggre-
gate of symptoms and signs associated with any morbid process, and constituting together the
picture of the disease” [24]. Within the context of MetS, an underlying unifying pathology of
Table 1. Baseline characteristics of matched individuals with MetS versus those with individual components of MetS.
Variable MetSa No MetS, 1 component p-Value No MetS, 2 components p-Value
N 690 690 690
Age (years)* 57.6±11.2 57.3±11.6 0.58 58.0±11.5 0.57
Male Sex* 52.2% 51.7% 0.87 51.2% 0.71
Family hx of CAD* 27.8% 28.8% 0.68 27.8% 1.00
Smoker* 16.5% 14.1% 0.20 15.7% 0.66
Hyperlipidemia 53.0% 50.7% 0.40 51.4% 0.55
Hypertension 70.4% 47.2% <0.001 58.0% <0.001
Diabetes Mellitus 33.9% 2.3% <0.001 13.5% <0.001
BMIb (kg/m2) 30.3±6.1 25.2±3.8 <0.001 27.6±5.0 <0.001
Chest Pain Symptoms
Asymptomatic 39.2% 38.9% 0.92 38.5% 0.80
Non Cardiac 4.7% 3.5% 0.29 3.7% 0.36
Atypical Angina 41.8% 45.0% 0.24 45.5% 0.18
Typical Angina 14.3% 12.5% 0.34 12.3% 0.29
a MetS = metabolic syndrome
b BMI = body mass index
*Matched variables
Table 2. Comparison of prevalence, extent and severity of coronary artery disease in matched individuals with versus without MetS based on
number of individual components of MetS.
Variable MetSc No MetS, 1 component p-Value No MetS, 2 components p-Value
Normal (%) 43.8% 58.3% <0.001 53.3% <0.001
Non Obstructive (%) 35.6% 30.0% 0.03 32.0% 0.16
Obstructive (%) 20.6% 11.7% <0.001 14.6% 0.003
Segment Stenosis Score 2.5±3.9 1.5±2.6 <0.001 1.9±3.1 <0.001
Obstructive 1 VD (%) 13.8% 8.4% 0.001 10.5% 0.06
Obstructive 2 VD (%) 4.5% 2.5% 0.04 2.8% 0.08
Obstructive 3 VDa/LMb (%) 2.3% 0.7% 0.02 1.3% 0.16
a VD = vessel disease
b LM = left main
c MetS = metabolic syndrome
doi:10.1371/journal.pone.0118998.t002
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insulin resistance and resultant energy dysregulation has been demonstrated to be associated
with increased risk for MACE and death [3–7]. The degree to which MetS confers this risk is
variable, with prior investigations suggesting that the components of MetS, when present to-
gether, results in a risk that is greater than the sum of its parts [25–28].
Yet little data exists when comparing the prevalence, extent and severity of CAD, as well as
risk of downstream adverse clinical events for patients with MetS versus those with underlying
individual components of MetS, particularly in individuals who are similar in other traditional
CAD risk factors. To our knowledge, these data represent the first to directly compare these
findings in patients with versus without MetS in a population similar in age, sex, smoking, and
family history of premature CAD. When examined against patients with MetS, we observed a
differential CAD profile and risk of downstream clinical adverse events for patients with 1 but
not 2 components of MetS.
These present data add to a body of literature that has observed inconsistent observations
regarding the concept of MetS as a clinical syndrome confers risk beyond its individual clinical
components. As an example, in the Atherosclerosis Risk in Communities (ARIC) study, meta-
bolic syndrome was observed to be associated with risk of 11-year cardiovascular outcomes, a
finding that was nevertheless mitigated by traditional risk factor scoring using the Framingham
Risk Score [29]. In contrast, patients with the Scandinavian Simvastatin Survival Study and the
Air Force/Texas Coronary Atherosclerosis Prevention Study demonstrated increase risk of
major coronary events above and beyond Framingham Risk Scores [30]. Our study differs and
Table 3. Incident MACE rates for matched patients with versus without MetS.
Annualized Event Rates All-Cause Mortality Myocardial Infarction MACEb
No MetSa (n = 1380) 0.5% 0.2% 0.8%
MetS (n = 690) 1.2% 0.1% 1.9%
p-Value 0.007 0.80 0.002
No MetS, 1 component (n = 690) 0.3% 0.1% 0.6%
No MetS, 2 components (n = 690) 0.7% 0.3% 1.1%
MetS (n = 690) 1.2% 0.1% 1.9%
p-Value (for trend) 0.009 0.22 0.003
a MetS = metabolic syndrome
b MACE = major adverse cardiac events
doi:10.1371/journal.pone.0118998.t003
Table 4. Hazards ratios for incident MACE for patients with versus without MetS.
Hazard Ratios Death (95% CI) p-Value MIb (95% CIc) p-Value MACE (95% CI) p-Value
No MetSa (n = 1380) 1.0 Reference 1.0 Reference 1.0 Reference
MetS (n = 690) 2.4 (1.2–4.7) 0.009 0.8 (0.2–4.0) 0.80 2.2 (1.3–3.7) 0.003
No MetS, 1 components (n = 690) 1.0 Reference 1.0 Reference 1.0 Reference
No MetS, 2 components, (n = 690) 2.5 (0.9–7.0) 0.09 5.2 (0.6–44.5) 0.13 2.0 (0.9–4.2) 0.08
MetS (n = 690) 4.2 (1.5–11.2) 0.005 2.5 (0.2–27.4) 0.46 3.3 (1.6–6.7) 0.001
a MetS = metabolic syndrome
bMI = myocardial infarction
cCI = confidence interval
doi:10.1371/journal.pone.0118998.t004
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is directly additive to these prior investigations in that we examined risk for patients undergo-
ing non-invasive angiography, and on a backdrop of CAD risk factor similarity.
This study is not without limitations. First, the study includes patients undergoing clinical
indicated CCTA studies and whether the present results can be extrapolated to a population-
based cohorts remains unknown. Furthermore, despite the prospective multinational nature of
study in this patient cohort, it nevertheless remains observational in nature and the potential
biases associated with all such studies cannot be discounted. Third, we employed BMI, diabetes
and hypertension as surrogates for components of MetS and whether greater precision would
have been observed had measures of waist circumference, triglycerides, low-density lipopro-
teins, high-density lipoproteins and fasting plasma glucose been available. Fourth, the down-
stream effects of the presence of MetS and its individual components are unknown, including
the use of medical therapies, lifestyle modification, and interventional procedures. Finally,
while our study represents the largest one of its kind to date, the number of MACE observed
were generally low and therefore our study might be underpowered to show a significant differ-
ence between those who presented with 2 MetS risk factors and patients with MetS.
Conclusion
Prevalence, extent, severity of CAD, and risk of MACE rates are significantly increased among
patients with MetS compared to those with only 1 component of MetS. This finding is observed
for patients with a single clinical component of MetS and not for patients with two components
of MetS.
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